FindTrial
Sign In

Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

DRUG2 trials

Sponsors

Mayo Clinic

Conditions

CholangiocarcinomaRectal AdenocarcinomaRecurrent Rectal CarcinomaStage III Gallbladder Cancer AJCC v7Stage IIIA Gallbladder Cancer AJCC v7Stage IIIB Gallbladder Cancer AJCC v7Stage IV Gallbladder Cancer AJCC v7Stage IV Rectal Cancer AJCC v7

Phase 1

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery
CompletedNCT03297710
Mayo ClinicRectal Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IVA Rectal Cancer AJCC v7 +2
Start: 2017-12-11End: 2021-04-30Updated: 2023-01-05

Phase 2

TAS-102 in Treating Advanced Biliary Tract Cancers
CompletedNCT03278106
Mayo ClinicCholangiocarcinoma, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7 +4
Start: 2017-10-20End: 2021-09-16Updated: 2023-06-28

Related Papers

A phase II trial of trifluridine/tipiracil plus oxaliplatin in patients with advanced or metastatic biliary tract cancer following first-line therapy.
Journal of Clinical Oncology2026-05-28
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma
The Oncologist2023-06-201 citations
Phase I trial of TAS-102 and concurrent radiation therapy for patients with locally recurrent, unresectable or metastatic, rectal cancer.
Journal of Clinical Oncology2018-05-201 citations